- Home
- MGNX vs EPSN Comparison
MGNX vs EPSN Comparison
Compare MGNX & EPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- EPSN
- Stock Information
- Founded
- MGNX 2000
- EPSN 2005
- Country
- MGNX United States
- EPSN Canada
- Employees
- MGNX N/A
- EPSN N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- EPSN Oil & Gas Production
- Sector
- MGNX Health Care
- EPSN Energy
- Exchange
- MGNX Nasdaq
- EPSN Nasdaq
- Market Cap
- MGNX 151.9M
- EPSN 153.4M
- IPO Year
- MGNX 2013
- EPSN N/A
- Fundamental
- Price
- MGNX $2.20
- EPSN $6.96
- Analyst Decision
- MGNX Hold
- EPSN Strong Buy
- Analyst Count
- MGNX 10
- EPSN 1
- Target Price
- MGNX $7.17
- EPSN $7.00
- AVG Volume (30 Days)
- MGNX 551.0K
- EPSN 40.6K
- Earning Date
- MGNX 05-08-2025
- EPSN 05-07-2025
- Dividend Yield
- MGNX N/A
- EPSN 3.58%
- EPS Growth
- MGNX N/A
- EPSN N/A
- EPS
- MGNX N/A
- EPSN 0.24
- Revenue
- MGNX $141,329,000.00
- EPSN $31,145,315.00
- Revenue This Year
- MGNX $177.84
- EPSN $4.92
- Revenue Next Year
- MGNX N/A
- EPSN $82.65
- P/E Ratio
- MGNX N/A
- EPSN $29.10
- Revenue Growth
- MGNX 16.68
- EPSN N/A
- 52 Week Low
- MGNX $2.15
- EPSN $4.92
- 52 Week High
- MGNX $19.54
- EPSN $7.09
- Technical
- Relative Strength Index (RSI)
- MGNX 35.93
- EPSN 64.81
- Support Level
- MGNX $2.16
- EPSN $6.52
- Resistance Level
- MGNX $2.49
- EPSN $7.09
- Average True Range (ATR)
- MGNX 0.17
- EPSN 0.24
- MACD
- MGNX -0.00
- EPSN 0.05
- Stochastic Oscillator
- MGNX 7.87
- EPSN 88.60
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.